Form 8-K · Current report
Pfizer 8-K, filed Nov 3, 2026
- Filed
- CIK
- 0000078003
- Accession no.
- 0000078003-26-000125
Summary
Pfizer reported third-quarter 2026 revenues of $16.6 billion, roughly flat year over year, and raised its full-year 2026 guidance for revenues to $62.0–$64.0 billion and for adjusted diluted EPS to $2.95–$3.05. Pfizer also appointed Cecile Guegan as Chief Financial Officer and Executive Vice President.
Key points
- Third-quarter 2026 revenues were $16.6 billion, relatively flat year over year operationally; excluding Comirnaty and Paxlovid, revenues grew 7% operationally and launched and acquired products grew 32% operationally.
- Reported diluted EPS was $0.56 and adjusted diluted EPS was $0.87 for the quarter, with reported net income down 8% to $3.24 billion.
- Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to $62.0–$64.0 billion and raised and narrowed adjusted diluted EPS guidance to $2.95–$3.05, including an approximately $0.10 unfavorable impact from a one-time $650 million acquired IPR&D charge tied to an in-licensing and collaboration agreement with Innovent Biologics.
- Cecile Guegan was appointed Chief Financial Officer and Executive Vice President.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On November 3, 2026, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the third quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.